Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | suspended | Phase 1 / Phase 2 | 30 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06709131 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia(CT0991) | suspended | Phase 1 | 24 | He HuangOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | suspended | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06940570 | Methadone as an Alternative Treatment for Children Underdoing HSCT(MATCH) | suspended | Phase 3 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04300335 | The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma | suspended | N/A | 45 | Medical University of ViennaOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06639958 | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home | suspended | N/A | 64 | Children's Oncology GroupNETWORK | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04668365 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma | suspended | Phase 2 | 59 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03187210 | Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas(BAL) | suspended | Phase 1 / Phase 2 | 20 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04668768 | HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma | suspended | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 210 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | suspended | Phase 1 | 16 | Syros PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 9 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | suspended | Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | suspended | Phase 1 / Phase 2 | 40 | Myeloid TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice(REVEAL) | suspended | — | 272 | AbbVieINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | suspended | Phase 1 / Phase 2 | 222 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | suspended | N/A | 20 | Bioray LaboratoriesINDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04746131 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) | suspended | Phase 1 | 90 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | suspended | Phase 2 | 120 | Shanghai Zhangjiang Biotechnology Limited CompanyINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03752541 | Efficacy and Safety Evaluation of BCMA-UCART | suspended | N/A | 20 | Bioray LaboratoriesINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT04697290 | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | suspended | Early Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02910752 | CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation | suspended | Phase 1 / Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03722186 | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies | suspended | Phase 1 | 128 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 22, 2021 | clinicaltrials |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia | suspended | Phase 1 | 20 | National University Health System, SingaporeOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT01755325 | Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ | suspended | Phase 3 | 680 | Junmin LiOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02462265 | Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients | suspended | Phase 2 | 15 | Oshadi Drug AdministrationINDUSTRY | 0 | Apr 18, 2018 | clinicaltrials |
| NCT01709396 | ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS(ED-TBI) | suspended | Phase 2 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00892346 | Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma | suspended | Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) | suspended | Phase 1 / Phase 2 | 120 | Humanigen, Inc.INDUSTRY | 2 | Nov 17, 2015 | clinicaltrials |
| NCT01010373 | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients | suspended | Phase 2 | 12 | BioMAS LtdINDUSTRY | 1 | Feb 10, 2015 | clinicaltrials |
| NCT01921998 | Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy(BioACT) | suspended | — | 50 | The Christie NHS Foundation TrustOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | suspended | Phase 1 | 36 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00991744 | Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) | suspended | Phase 3 | 100 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Oct 10, 2012 | clinicaltrials |
| NCT00077493 | BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | suspended | Phase 1 | 95 | MedImmune LLCINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | suspended | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 26, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jan 15, 2026source: clinicaltrials